BioDelivery Sciences

BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BioDelivery Sciences International (BDSI) Report Negative Q1 Earnings? What You Should Know

Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

What's in Store for BioDelivery (BDSI) This Earnings Season?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

BioDelivery Buys US Rights to Pain Drug for $30M

Bed Bath & Beyond

Key Tronic

SemiLEDs

Stocks Moving In Wednesday's After-Hours Session: Gainers & Losers.

4 Stocks Moving In Wednesday's After-Hours Session

BioDelivery Sciences International (BDSI) closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day.

BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know

BioDelivery Sciences International (BDSI) closed the most recent trading day at $5.30, moving +0.57% from the previous trading session.

BioDelivery Sciences International (BDSI) Gains But Lags Market: What You Should Know

BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q4 2018 Results - Earnings Call Transcript

We are short BioDelivery Sciences International (BDSI), a money losing opioid manufacturer that was co-founded by Dr. Frank O’Donnell, Jonnie Williams’ long-time business partner.

BioDelivery Sciences - A Money Losing Opioid Company Founded By The Bankruptcy Experts

News for BioDelivery Sciences Stock (BDSI)